- ROUNDTABLE: Pharmacy’s future in sync with technology
- Mylan launches generic version of Prandin
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Ensuring access to chronic pain medications
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
PITTSBURGH — Mylan and Orion Corp. have settled a patent-infringement suit over a drug used to treat Parkinson's disease, Mylan said Thursday.
The generic drug maker had filed with the Food and Drug Administration for a generic version of Orion's Stalevo (carpidopa; levodopa; entacapone) tablets, used to treat idiopathic Parkinson's to substitute for immediate-release carbidopa/levodopa and entacapone administered separately.
Under the agreement, Mylan can immediately launch an authorized generic version of Stalevo and then launch its own generic after the FDA approves it. An authorized generic is the original branded drug marketed under its generic name at a discount, usually through a third-party company. Mylan is seeking approval for the drug in the 12.5-mg/50-mg/200-mg, 18.75-mg/75-mg/200-mg, 25-mg/100-mg/200-mg, 31.25-mg/125-mg/200-mg, 37.5-mg/150-mg/200-mg and 50-mg/200-mg/200-mg strengths.
Stalevo had sales of about $138.6 million during the 12-month period that ended in March, according to IMS Health.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.